NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-.

Cover of Drugs and Lactation Database (LactMed)

Drugs and Lactation Database (LactMed) [Internet].

Show details

Agalsidase Alfa

Last Revision: April 20, 2020.

Estimated reading time: 1 minute

CASRN: 104138-64-9

Drug Levels and Effects

Summary of Use during Lactation

Agalsidase alfa is not approved for marketing in the United States by the U.S. Food and Drug Administration, but is available in other countries. Because it is a large protein molecule with a molecular weight of about 100,000, the amount in milk is likely to be very low and absorption is unlikely because it is probably destroyed in the infant's gastrointestinal tract. Six infants who were breastfed for periods up to 12 months by mothers taking agalsidase alfa experienced no adverse effects associated with the drug.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Six patients with Fabry disease were treated with agalsidase alfa 0.2 mg/kg every 2 weeks during pregnancy and postpartum. One infant partially breastfed for 10 months had asthma at age 4 years and an infant who was partially breastfed for 5 months had recurrent urinary tract infections up to 2 years, but was normal at the age of 5 years. Three infants who were exclusively breastfed for 6 months and partially breastfed until 12 months and one partially breastfed for 12 months were normal. None of the adverse effects appear to have been associated with agalsidase alfa.[1]

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Alternate Drugs to Consider

Agalsidase Beta

References

1.
Fernandez P, Fernandez SO, Gonzalez JGM, et al. Enzyme replacement therapy in pregnant women with Fabry disease A case series. JIMD Rep. 2019;45:77–81. [PMC free article: PMC6336548] [PubMed: 30406505]

Substance Identification

Substance Name

Agalsidase Alfa

CAS Registry Number

104138-64-9

Drug Class

Breast Feeding

Lactation

Enzymes

Enzyme Replacement Therapy

alpha-Galactosidase

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Views

Related information

  • PMC
    PubMed Central citations
  • PubMed
    Links to PubMed

Similar articles in PubMed

  • Review Agalsidase Beta[Drugs and Lactation Database (...]
    Review Agalsidase Beta
    . Drugs and Lactation Database (LactMed). 2006
  • Review Dornase Alfa[Drugs and Lactation Database (...]
    Review Dornase Alfa
    . Drugs and Lactation Database (LactMed). 2006
  • Review Interferon Alfa[Drugs and Lactation Database (...]
    Review Interferon Alfa
    . Drugs and Lactation Database (LactMed). 2006
  • Review Alglucosidase Alfa[Drugs and Lactation Database (...]
    Review Alglucosidase Alfa
    . Drugs and Lactation Database (LactMed). 2006
  • Review Velaglucerase alfa[Drugs and Lactation Database (...]
    Review Velaglucerase alfa
    . Drugs and Lactation Database (LactMed). 2006
See reviews...See all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...